A pilot retrospective study validating noncommunicable disease risk assessment score (AMNRAS)
Background: Globally Noncommunicable Diseases is lead causes of mortality. This calls for the need of sensitive and cost appropriate screening tools to identify asymptomatic healthy individuals with higher risk and/or subclinical NCD in the community. The study aims to generate pilot evidence based,...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wolters Kluwer Medknow Publications
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/56550079204449be85408931ed2156e3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background: Globally Noncommunicable Diseases is lead causes of mortality. This calls for the need of sensitive and cost appropriate screening tools to identify asymptomatic healthy individuals with higher risk and/or subclinical NCD in the community. The study aims to generate pilot evidence based, validated, good quality, cost appropriate, and sustainable risk assessment score for NCD for developing countries like India. Methods: This descriptive retrospective study of diabetic camp data of 84 patients was conducted. A risk score having 10 questions and three measurements for NCDs appropriate for Indian communities was generated. It was compared to IDRS, FINDRISC, FRS, CBAC, and WHO/ISH prediction charts. Results: The study finally included 36 patients with NCD as case and 44 subjects without NCD as control. The means of weight, waist circumference, blood pressure, and blood sugar were significantly different among the two groups. AMNRAS of more than 14 was highly predictive for an individual to be at risk of NCD or sub clinical case of NCD requiring evaluation. The proposed cut-off of 8 for AMNRAS, the sensitivity and NPV was highest compared to other score, 88.9% and 84.6%, respectively. Score for the Area under curve was significantly higher for AMNRAS [0.83 (0.74 to 0.92)] compared to other scores. Conclusions: AMNRAS has higher performance parameters than the other five tested in the present study. Other scoring system performs only modestly in discrimination of NCD cases. The accuracy of AMNRAS for NCD risk will have to be determined in large size cohorts. |
|---|